Prebiotic effects of a novel combination of galactooligosaccharides and maltodextrins
Language English Country United States Media print-electronic
Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
25525835
DOI
10.1089/jmf.2013.0187
Knihovny.cz E-resources
- Keywords
- bifidobacteria, intestinal microbiota, oligosaccharides, prebiotics,
- MeSH
- Bifidobacterium drug effects growth & development metabolism MeSH
- Adult MeSH
- Escherichia coli drug effects growth & development metabolism MeSH
- Feces microbiology MeSH
- Drug Combinations MeSH
- Galactose pharmacology MeSH
- Fatty Acids, Volatile metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Oligosaccharides pharmacology MeSH
- Polysaccharides pharmacology MeSH
- Prebiotics * MeSH
- Intestines drug effects microbiology MeSH
- Gastrointestinal Microbiome drug effects MeSH
- Intestinal Mucosa metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Drug Combinations MeSH
- Galactose MeSH
- Fatty Acids, Volatile MeSH
- maltodextrin MeSH Browser
- Oligosaccharides MeSH
- Polysaccharides MeSH
- Prebiotics * MeSH
Prebiotics are used for stimulating the growth of beneficial microorganisms in the gut. However, it is very difficult to find a suitable prebiotic mixture that exclusively supports the growth of beneficial microbes such as bifidobacteria and lactobacilli. We tested the effects of a prebiotic mixture in vitro by incubating it with fecal samples and in vivo by administration of the prebiotic supplement to healthy adult volunteers, followed by analysis of their fecal microbiota. The effect of the oligosaccharides on bacterial metabolism was studied by analyzing short-chain fatty acid (SCFA) production in vitro and the SCFA pattern for the stool samples of volunteers. In the in vitro test, a higher proportion of bifidobacteria (25.77%) was seen in the total bacterial population after cultivation on a prebiotic mixture than on the control medium (7.94%). The gram-negative anaerobe count significantly decreased from 8.70 to 6.40 log CFU/g (from 35.21% to 0.60%) and the Escherichia coli count decreased from 7.41 to 6.27 log CFU/g (from 1.78% to 0.44%). Administration of a prebiotic mixture in vivo (9 g of galactooligosaccharides [GOS]+1 g of maltodextrins; daily for 5 days) significantly increased the fecal bifidobacterial count from 9.45 to 9.83 log CFU/g (from 40.80% to 53.85% of total bacteria) and reduced the E. coli count from 7.23 to 6.28 log CFU/g (from 55.35% to 45.06% of total bacteria). The mixture comprising GOS and maltodextrins thus exhibited bifidogenic properties, promoting the performance of bifidobacteria by boosting their growth and inhibiting the growth of undesirable bacteria.
References provided by Crossref.org